1. Phase 2 Study of Selinexor in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents: Interim Report. (April 2017) Authors: Klimek, V.M.; Coleman, M.; Alvarez, K.; Sen, F.; Pichardo, J.; Kashyap, T.; Klebanov, B. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗